ProMIS Neurosciences (PMN) Stock Price

ProMIS Neurosciences Price

NASDAQ·CLOSED
13.33USD+0.01 (+0.08 %)
Market closed

Revenue at ProMIS Neurosciences has contracted by 8.7% per year over the past 12 years to 10,000.00 USD. ProMIS Neurosciences's net margin stands at -46,400.0%, down from -4,460.0% several years earlier. Analysts set a median price target of 35.70 USD, implying 167.8% above the current price. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 97% above its 52-week low.

ProMIS Neurosciences stock price

Volume
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of ProMIS Neurosciences over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how ProMIS Neurosciences stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing ProMIS Neurosciences's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

ProMIS Neurosciences Stock Price History
DateProMIS Neurosciences Price
8/6/202613.33 USD
8/5/202613.32 USD
8/4/202614.00 USD
8/3/202614.14 USD
7/31/202613.72 USD
7/30/202614.92 USD
7/29/202613.81 USD
7/27/202611.90 USD
7/23/202612.61 USD
7/22/202613.99 USD
7/21/202614.49 USD
7/20/202615.08 USD
7/17/202615.19 USD
7/16/202613.30 USD
7/15/202614.01 USD
7/14/202613.66 USD
7/13/202613.18 USD
7/10/202614.25 USD
7/9/202614.27 USD
7/8/202613.65 USD
7/7/202613.55 USD
7/6/202613.50 USD
7/2/202613.35 USD
7/1/202613.45 USD
6/30/202613.16 USD
6/29/202610.75 USD
6/26/202610.53 USD
6/25/202610.25 USD
6/24/202610.24 USD
6/23/202610.69 USD
6/22/202610.81 USD
6/18/202610.54 USD
6/17/202610.38 USD
6/16/202610.16 USD
6/15/202610.05 USD
6/12/202610.35 USD
6/11/202610.70 USD
6/10/202610.20 USD
6/9/20269.75 USD
6/8/20269.71 USD
6/5/20269.13 USD
6/4/20269.73 USD
6/3/20269.65 USD
6/2/202610.15 USD
6/1/202610.41 USD
5/29/202610.81 USD
5/28/202610.87 USD
5/27/202610.48 USD
5/26/202610.36 USD
5/22/202610.98 USD
5/21/202610.85 USD
5/20/202610.60 USD
5/19/202610.65 USD
5/18/202610.44 USD
5/15/202610.39 USD
5/13/202610.57 USD
5/12/202610.49 USD
5/8/20269.83 USD
5/7/20269.83 USD
5/6/202611.00 USD
5/5/202611.06 USD
5/4/202611.07 USD
5/1/202611.01 USD
4/30/202611.04 USD
4/29/202611.15 USD
4/28/202610.85 USD
4/27/202611.10 USD
4/24/202611.24 USD
4/23/202610.88 USD
4/22/202611.11 USD
4/21/202610.73 USD
4/20/202611.45 USD
4/17/202611.53 USD
4/16/202611.84 USD
4/15/202612.30 USD
4/14/202612.05 USD
4/13/202612.92 USD
4/10/202612.60 USD
4/9/202612.50 USD
4/8/202610.70 USD
4/7/202610.88 USD
4/6/202610.96 USD
4/2/202612.51 USD
4/1/202613.00 USD
3/31/202612.70 USD
3/30/202612.88 USD
3/27/202614.74 USD
3/26/202615.13 USD
3/25/202615.85 USD
3/24/202617.43 USD
3/23/202617.77 USD
3/20/202617.60 USD
3/19/202618.21 USD
3/18/202617.00 USD
3/17/202619.55 USD
3/16/202620.16 USD
3/13/202618.15 USD
3/12/202619.95 USD
3/11/202620.09 USD
3/10/202621.69 USD
3/9/202623.77 USD
3/6/202623.40 USD
3/5/202624.79 USD
3/4/202624.05 USD
3/3/202624.60 USD
3/2/202622.79 USD
2/27/202623.51 USD
2/26/202620.86 USD
2/25/202619.86 USD
2/24/202617.96 USD
2/23/202615.79 USD
2/20/202616.09 USD
2/19/202616.16 USD
2/18/202616.29 USD
2/17/202616.17 USD
2/13/202615.25 USD
2/12/202614.96 USD
2/11/202614.61 USD
2/10/202614.29 USD
2/9/202613.05 USD
2/6/202612.73 USD
2/5/202613.10 USD
2/4/202615.65 USD
2/3/202615.90 USD
2/2/202614.05 USD
1/30/202614.16 USD
1/29/202612.01 USD
1/28/202612.08 USD
1/27/202610.66 USD
1/26/20268.97 USD
1/23/20269.43 USD
1/22/20269.25 USD
1/21/20268.25 USD
1/20/20268.16 USD
1/16/20268.18 USD
1/15/20268.15 USD
1/14/20268.14 USD
1/13/20268.16 USD
1/12/20268.21 USD
1/9/20268.13 USD
1/8/20268.48 USD
1/7/20268.26 USD
1/6/20267.69 USD
1/5/20267.40 USD
1/2/20267.14 USD
12/31/20256.83 USD
12/30/20256.99 USD
12/29/20257.37 USD
12/26/20257.66 USD
12/24/20258.27 USD
12/23/20258.13 USD
12/22/20258.13 USD
12/19/20258.55 USD
12/18/20258.42 USD
12/17/20258.92 USD
12/16/20259.34 USD
12/15/20259.24 USD
12/12/20258.99 USD
12/11/20258.76 USD
12/10/20259.10 USD
12/9/20258.13 USD
12/8/20257.62 USD
12/5/20257.91 USD
12/4/20257.63 USD
12/3/20257.36 USD
12/2/20257.44 USD
12/1/20257.00 USD
11/28/20256.76 USD
11/26/20257.25 USD
11/25/20258.00 USD
11/24/20258.25 USD
11/21/202510.50 USD
11/20/20259.50 USD
11/19/202510.50 USD
11/18/20259.00 USD
11/17/20259.00 USD
11/14/20259.75 USD
11/13/20259.75 USD
11/12/202510.25 USD
11/11/202510.00 USD
11/10/20259.75 USD
11/7/20259.50 USD
11/6/20259.75 USD
11/5/202510.25 USD
11/4/202510.25 USD
11/3/202510.25 USD
10/31/202510.50 USD
10/30/202510.50 USD
10/29/202510.50 USD
10/28/202511.00 USD
10/27/202511.50 USD
10/24/202510.75 USD
10/23/202510.75 USD
10/22/202510.50 USD
10/21/202511.00 USD
10/20/202511.25 USD
10/17/202511.00 USD
10/16/202511.75 USD
10/15/202512.00 USD
10/14/202511.50 USD
10/13/202512.00 USD
10/10/202512.25 USD
10/9/202512.75 USD
10/8/202514.25 USD
10/7/202513.50 USD
10/6/202513.75 USD
10/3/202512.50 USD
10/2/202511.75 USD
10/1/202511.50 USD
9/30/202510.75 USD
9/29/202511.00 USD
9/26/202510.25 USD
9/25/202510.00 USD
9/24/202510.25 USD
9/23/202510.25 USD
9/22/202510.75 USD
9/19/202511.00 USD
9/18/202511.50 USD
9/17/202511.50 USD
9/16/202510.50 USD
9/15/202510.50 USD
9/12/202511.00 USD
9/11/202510.50 USD
9/10/202510.00 USD
9/9/202510.50 USD
9/8/202511.00 USD
9/5/202510.75 USD
9/4/202510.75 USD
9/3/202511.50 USD
9/2/202513.50 USD
8/29/202513.50 USD
8/28/202513.25 USD
8/27/202513.25 USD
8/26/202513.75 USD
8/25/202513.25 USD
8/22/202513.50 USD
8/21/202513.75 USD
8/20/202513.00 USD
8/19/202514.00 USD
8/18/202515.50 USD
8/15/202515.50 USD
8/14/202515.75 USD
8/13/202517.50 USD
8/12/202517.50 USD
8/11/202515.75 USD
Access this data via the Eulerpool API

ProMIS Neurosciences Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
0.00 USD
-8.29 M USD
-9.79 M USD
Jan 1, 2022
0.00 USD
-23.38 M USD
-18.06 M USD
Jan 1, 2023
0.00 USD
-14.26 M USD
-13.21 M USD
Jan 1, 2024 (e)
0.00 USD
-19.42 M USD
-2.99 M USD
Jan 1, 2025 (e)
0.00 USD
-36.00 M USD
-49.84 M USD
Jan 1, 2026 (e)
0.00 USD
-40.99 M USD
-17.99 M USD
Jan 1, 2027 (e)
0.00 USD
-58.67 M USD
-9.82 M USD
Jan 1, 2028 (e)
0.00 USD
0.00 USD
-11.16 M USD

ProMIS Neurosciences Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 9, 2026, 9:09 PM
 
REVENUEk USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201320142015201620172018201920202021202220232024e2025e2026e2027e2028e
-2.00-1.00-1.00-2.00-4.00-7.00-5.00-4.00-8.00-23.00-14.00-19.00-35.00-40.00-58.00
-2.00-1.00-1.00-2.00-4.00-7.00-5.00-4.00-9.00-18.00-13.00-2.00-49.00-17.00-9.00-11.00
-50.00100.00100.0075.00-28.57-20.00125.00100.00-27.78-84.622,350.00-65.31-47.0622.22
1.010.050.070.110.140.160.170.190.230.300.490.490.490.490.490.49
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales ProMIS Neurosciences generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue ProMIS Neurosciences retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare ProMIS Neurosciences's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares ProMIS Neurosciences has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against ProMIS Neurosciences's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

ProMIS Neurosciences stock margins

The ProMIS Neurosciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ProMIS Neurosciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ProMIS Neurosciences.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
0.00 %
- %
- %
Jan 1, 2020
0.00 %
- %
- %
Jan 1, 2021
0.00 %
- %
- %
Jan 1, 2022
0.00 %
- %
- %
Jan 1, 2023
0.00 %
- %
- %
Jan 1, 2024 (e)
0.00 %
- %
- %
Jan 1, 2025 (e)
0.00 %
- %
- %
Jan 1, 2026 (e)
0.00 %
- %
- %

ProMIS Neurosciences Stock Revenue, EBIT, Earnings per Share

The ProMIS Neurosciences earnings per share therefore indicates how much revenue ProMIS Neurosciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2019
0.00 USD
-805.43 USD
-805.43 USD
Jan 1, 2020
0.00 USD
-554.10 USD
-554.10 USD
Jan 1, 2021
0.00 USD
-895.64 USD
-1,057.69 USD
Jan 1, 2022
0.00 USD
-1,947.68 USD
-1,504.50 USD
Jan 1, 2023
0.00 USD
-725.17 USD
-671.78 USD
Jan 1, 2024 (e)
0.00 USD
-987.42 USD
-34.72 USD
Jan 1, 2025 (e)
0.00 USD
-1,830.19 USD
-579.49 USD
Jan 1, 2026 (e)
0.00 USD
-2,083.93 USD
-209.20 USD

ProMIS Neurosciences business model & stock analysis

ProMIS Neurosciences Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

ProMIS Neurosciences historical P/E ratio, EBIT multiple, and P/S ratio

ProMIS Neurosciences annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

ProMIS Neurosciences shares outstanding

The number of shares of ProMIS Neurosciences was 19,668 in 2025. This indicates how many shares ProMIS Neurosciences is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2019
6,928.00 Stocks
Jan 1, 2020
7,616.00 Stocks
Jan 1, 2021
9,256.00 Stocks
Jan 1, 2022
12,004.00 Stocks
Jan 1, 2023
19,668.00 Stocks
Jan 1, 2024 (e)
19,668.00 Stocks
Jan 1, 2025 (e)
19,668.00 Stocks
Jan 1, 2026 (e)
19,668.00 Stocks

ProMIS Neurosciences stock splits

In ProMIS Neurosciences's history, there have been no stock splits.

Current ProMIS Neurosciences forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
87.50 % (7)
Hold
12.50 % (1)
Sell
0.00 % (0)
12M Price Target
35.70
Last Price
14.71
Currency
USD
12M Return Potential
142.69 %
LTM Return
0 %

ProMIS Neurosciences Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/11/2026-1.39USD-0.00USD-2026 Q2
5/11/2026-1.49USD-0.00USD-2026 Q1
3/30/2026-4.93USD-0.00USD-2025 Q4
11/13/2024-0.07USD-0.00USD-2024 Q3

ProMIS Neurosciences shareholder structure

% Name
43.86465%
Ally Bridge Group NY LLC
Ally Bridge Group NY LLC
41.97958%
Deep Track Capital LP
Deep Track Capital LP
25.91177%
Trails Edge Capital Partners LP
Trails Edge Capital Partners LP
0.57660%
Williams (Eugene Warren)
Williams (Eugene Warren)
0.54916%
Sphera Funds Management Ltd.
Sphera Funds Management Ltd.
0.39121%
Milbury (Max A.)
Milbury (Max A.)

ProMIS Neurosciences Executives and Management Board

12 members · avg. age 67 · 25 % women

NW

Mr. Neil Warma (62)

President, Chief Executive Officer, Director · since 2021

2.34 M USD

Management

JK

Dr. Johanne Kaplan (65)

Chief Development Officer

664,603.00 USD
NC

Dr. Neil Cashman (73)

Chief Scientific Officer, Director · since 2004

515,886.00 USD
DG

Mr. Daniel Geffken (68)

Chief Financial Officer

180,066.00 USD
LA

Mr. Larry Altstiel (75)

Chief Medical Officer

AF

Ms. Anne Marie Fields

Managing Director · since 2024

Board of Directors

EW

Mr. Eugene Williams (65)

Chairman of the Board · since 2015

84,968.00 USD
MS

Ms. Maggie Shafmaster (66)

Lead Independent Director

74,968.00 USD
PK

Mr. Patrick Kirwin (68)

Independent Director

74,968.00 USD
JM

Mr. Josh Mandel-Brehm (42)

Independent Director

74,968.00 USD
WW

Mr. William Wyman (87)

Independent Director

74,968.00 USD
SA

Dr. Slanix Alex

Director

Frequently asked questions about ProMIS Neurosciences

Analysts currently set an average price target of 35.06 USD for the ProMIS Neurosciences stock (median: 35.70 USD), implying +138.4 % versus the latest price. The consensus is based on 8 analyst ratings.

8 analysts currently rate the ProMIS Neurosciences stock: 7 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the ProMIS Neurosciences share trades at 11.54 EUR (13.33 USD).

The ProMIS Neurosciences share (PMN) is listed on 2 stock exchanges, including: NASDAQ (PMN), Frankfurt (23J0.F).

No history available for ProMIS Neurosciences.

The revenue cannot currently be calculated for ProMIS Neurosciences.

The expected profit of ProMIS Neurosciences is -17.99 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of ProMIS Neurosciences is currently -0.01. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the ProMIS Neurosciences stock.

The P/S cannot be calculated for ProMIS Neurosciences currently.

The Eulerpool Quality Score for ProMIS Neurosciences is 2/10.

The ISIN of ProMIS Neurosciences is CA74346M4065. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of ProMIS Neurosciences is A3DM9Q. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of ProMIS Neurosciences is PMN. The ticker symbol is used to trade ProMIS Neurosciences shares on the stock exchange.

ProMIS Neurosciences paid dividends every year for the past 0 years.

ProMIS Neurosciences is assigned to the 'Health' sector.

The dividends of ProMIS Neurosciences are distributed in USD.